Company intelligence / Profile preview

Imugen

Sydney, New South Wales, Australiafda.gov ↗

Ownership: Private
Development stage: Commercial

Overview

Imugene has demonstrated early clinical activity with its HER-Vaxx vaccine in gastric cancer and has advanced several novel immuno-oncology candidates into the clinic. Its CF33 oncolytic virus platform and PD1-Vaxx are being evaluated in various solid tumor settings. The company’s technologies aim to harness the immune system to recognize and eradicate cancers, with ongoing trials showing promising safety profiles and initial efficacy signals.

Therapeutic areas: Oncology
Modalities: VaccineOncolytic virus therapyMonoclonal antibodyPeptidesSmall molecule
Industry: Biotech

Partnerships

Ohio State UniversityMayo ClinicCity of Hope Cancer CenterMedical University of Vienna

Beyond the preview

Go deeper on Imugen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Imugen.

Explore the full profile